Biotechnology

Apogee Therapeutic

Apogee Therapeutic released FY2026 Q1 earnings on May 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.0637 (forecast USD -1.0822)

Apogee Therapeutics CEO Sells Shares and Completes New Share Issuance

Apogee Therapeutic released FY2025 Annual Earnings on March 2, 2026 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -4.2155 (forecast USD -4.2004)

Apogee Therapeutic released FY2025 Q4 earnings on March 2, 2026 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.03 (forecast USD -1.0239)

Apogee Therapeutics Reports FY2025 Net Loss, Increased R&D Expenses, and Positive Clinical Trials for Zumilokibart

Apogee Therapeutics Inc. CEO Selling Company Common Stock

Apogee Therapeutic released FY2025 Q3 earnings on November 10 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.1062 (forecast USD -1.162)

Apogee Therapeutic released FY2025 9 Months Earnings on November 10 (EST), with actual revenue of USD 0 and EPS of USD -3.1884

Apogee Therapeutic released FY2025 Semi-Annual Earnings on August 11 (EST) with actual revenue of USD 0 and EPS of USD -2.0785

Apogee Therapeutic released FY2025 Q2 earnings on August 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.1312 (forecast USD -1.0871)

Apogee Therapeutic released FY2025 Q1 earnings on May 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.9509 (forecast USD -1.2616)

Apogee Therapeutic released FY2024 annual earnings on March 3 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -3.3001 USD (forecast -3.0342 USD)

Apogee Therapeutic released FY2024 Q4 earnings on March 3, 2025 (EST), actual EPS -1.1741 USD (forecast -1.03 USD)

Apogee Therapeutic released FY2024 Q3 earnings on November 12 (EST), actual EPS -0.863 (forecast -0.7683)

Apogee Therapeutic released FY2024 9 Months Earnings on November 12 (EST), with actual revenue of 0 and EPS of -2.1008

ProShare Advisors LLC acquires new shares of Apogee Therapeutics with other institutional investors

Apogee Therapeutics Inc: Proposed Stock Underwriting Public Offering

Apogee Therapeutics Inc announces positive mid-term results of new drug APG777 in the treatment of atopic dermatitis

Liminatus Pharma

NewGenIvf

Co-Diagnostics

Agape ATP

Sunshine Biopharma

Tradr 2X Long QBTS Daily ETF

Defiance Daily Target 2X Long RGTI ETF

Tradr 2X Long RGTI Daily ETF

Wheeler Real Estate

Tradr 2X Long APLD Daily ETF

APGE

SBIO

LABU

Canaccord Genuity analyst Edward Nash has maintained a Buy rating for Apogee Therapeutics (APGE) with a price target of $130.00. The analyst has an average return of 25.7% and a 50.48% success rate on his stock recommendations. The overall analyst consensus for Apogee Therapeutics is a Strong Buy, with an average price target of $122.25.

Tip Ranks

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

Corcept Therap

Travere Therapeutics

Kiniksa Pharmaceuticals

Canaccord Genuity Sticks to Their Buy Rating for Apogee Therapeutics (APGE)

Apogee Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.

benzinga_article

Earnings Watch

Apogee Therapeutic | 10-Q: FY2026 Q1 Revenue: USD 0

Apogee Therapeutic | 8-K: FY2026 Q1 Revenue: USD 0

IBBQ

Apog announced the resignations of Andrew Gottesdiener, M.D. and Peter Harwin from its board, effective May 11, 2026. The resignations are not due to any disagreements with the company regarding its operations, policies, or practices. Replacement information has not been disclosed. This announcement was filed with the SEC as part of Apogee Therapeutics, Inc.'s 8-K on April 24, 2026.

TradingView

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Apog appoints resignations of Andrew Gottesdiener and Peter Harwin from board

Apogee Therapeutics CEO Michael Thomas Henderson sold 20,000 shares as part of a pre-arranged plan, while the company raised approximately US$403 million through a public offering of 5.75 million shares at US$70.00 each. T. Rowe Price disclosed a 16.8% ownership stake, indicating strong institutional interest. Despite the capital raise easing financing risks, concerns about dilution and ongoing losses remain. Valuation estimates vary significantly, highlighting differing investor perspectives on funding risks and trial outcomes. Investors are advised to conduct thorough research before making decisions.

Simplywall

How Investors May Respond To Apogee Therapeutics (APGE) CEO Share Sale and US$403 Million Equity Raise

AOGO

APOG

Apogee Acquisition Corp Announces Closing of $172.5 Million Initial Public Offering | AACP Stock News

StockTitan

Arogo Capital Acquisition

Apogee Enterprises

Apogee Acquisition Corp Announces Closing of $172.5 Million Initial Public Offering | AACP Stock News

Apogee Acquisition Corp Announces Pricing of $150 Million Initial Public Offering | AACP Stock News

Apogee Acquisition Corp Announces Pricing of $150 Million Initial Public Offering | AACP Stock News

Apogee Therapeutic(APGE.US)

Canaccord Genuity Sticks to Their Buy Rating for Apogee Therapeutics (APGE)

Apogee Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.

Apogee Therapeutic | 10-Q: FY2026 Q1 Revenue: USD 0

Apogee Therapeutic | 8-K: FY2026 Q1 Revenue: USD 0

Apog appoints resignations of Andrew Gottesdiener and Peter Harwin from board

How Investors May Respond To Apogee Therapeutics (APGE) CEO Share Sale and US$403 Million Equity Raise

Apogee Acquisition Corp Announces Closing of $172.5 Million Initial Public Offering | AACP Stock News

Apogee Acquisition Corp Announces Pricing of $150 Million Initial Public Offering | AACP Stock News